 Relay Therapeutics Inc NASDAQ: RLAY has announced an interim data Phase 1 trial of RLY-4008 in FGFR2-altered cholangiocarcinoma bile duct cancer and multiple other solid tumors. The data were shared at the AACR-NCI-EORTC Molecular Targets Conference. 